10-Q: GoodRx Holdings Q1 2026 Earnings Decline Amidst Market Shifts

GoodRx Holdings reports a decrease in revenue and net income for Q1 2026, impacted by retail pharmacy landscape changes and a shift towards Pharma Direct offerings.

Summary

• GoodRx Holdings reported a decrease in total revenue to $194.0 million for the first quarter of 2026, down from $203.0 million in the same period of 2025.
• Net income for the quarter was $1.2 million, a significant drop from $11.1 million in Q1 2025, with net income margin falling to 0.6% from 5.4%.
• Adjusted EBITDA also declined to $58.3 million from $69.8 million, with Adjusted EBITDA Margin decreasing to 30.0% from 34.4%.
• Prescription transactions revenue saw a substantial decrease of 24% year-over-year, attributed to changes in the retail pharmacy landscape and a reduction in an integrated savings program.
• Pharma Direct revenue experienced significant growth, increasing by 82% year-over-year, driven by expanded market penetration with pharmaceutical manufacturers.
• Subscription revenue grew by 16%, supported by the introduction of new condition-specific programs and an increase in subscription plans.
• The company is strategically shifting focus towards its Pharma Direct and subscription offerings, anticipating near-term impacts on prescription transaction unit economics and revenue in 2026, while aiming for enhanced long-term growth prospects.
• A significant legal settlement provision of $25.0 million for a consumer privacy class action, plus $5.5 million for indemnification, is recorded as of March 31, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the significant decline in revenue, net income, and key operating metrics, despite positive growth in specific segments like Pharma Direct.

Positives

• Pharma Direct revenue increased by 82% to $52.2 million, indicating strong growth in this strategic area.
• Subscription revenue grew by 16% to $24.4 million, with an increase in subscription plans to 717,000.
• The company maintains a strong liquidity position with $235.7 million in cash and cash equivalents and $80.4 million available under its revolving credit facility.
• GoodRx is a key integration partner for pharmaceutical manufacturers on the new government-sponsored TrumpRx.gov platform, with initial demand concentrated in GLP-1 therapies appearing incremental.
• The company is actively expanding its Pharma Direct offering, including a collaboration with a pharmaceutical manufacturer for significant discounts on key medications like Lipitor and Viagra.
• The company launched Employer Direct, a new platform to help employers address healthcare affordability gaps.

Negatives

• Total revenue decreased by 4% to $194.0 million in Q1 2026 compared to $203.0 million in Q1 2025.
• Net income decreased by 89% to $1.2 million from $11.1 million year-over-year.
• Prescription transactions revenue decreased by 24% to $113.7 million, significantly impacting overall revenue.
• Monthly Active Consumers decreased to 5.3 million in Q1 2026 from 6.4 million in Q1 2025.
• Cost of revenue increased by 51% to $20.2 million, driven by increased delivery, fulfillment, and subscription-related costs.
• The company recorded a $4.4 million impairment loss on an operating lease asset in the prior year's quarter (Q1 2025).

Risks

• The impact of store closures and bankruptcy of retail partners (e.g., Rite Aid) on claims volume and recapture of these claims.
• Heightened renegotiations between pharmacies and PBMs, leading to changes in retailer reimbursement models.
• Material volume reduction in integrated savings programs due to PBM implementation and management decisions.
• The potential impact of the new government-sponsored TrumpRx.gov platform on GoodRx's business, offerings, or results of operations remains uncertain and could be material.
• The company's significant reliance on its prescription transactions offering and its ability to expand other offerings.
• Changes in medication pricing and the impact of pricing structures negotiated by industry participants.
• Risks related to pandemics, epidemics, or outbreaks of infectious disease.
• The accuracy of the company's estimate of its addressable market and other operational metrics.
• Risks related to government regulation of the internet, e-commerce, consumer data, privacy, information technology, and cybersecurity.
• The potential for failure to comply with applicable data protection, privacy, and security laws.
• The risk that the company may be unable to realize expected benefits from its restructuring and cost reduction efforts.
• Risks related to debt arrangements and the company's ability to service its debt.
• The potential for interruptions or delays in service on its apps or websites.
• The company's reliance on third-party platforms for distribution.
• The increasing focus on environmental sustainability and social initiatives.
• Litigation risks, including the ongoing consumer privacy class action and consumer state litigations.
• General economic factors, natural disasters, or other unexpected events.
• The potential adverse effects of healthcare reform legislation and other proposed or future changes impacting the healthcare industry and healthcare spending.

Future Outlook

The company expects near-term impacts on prescription transaction unit economics and revenue in 2026 due to the transition towards Pharma Direct and subscription offerings, but believes this shift enhances long-term growth prospects and value creation. The potential impact of TrumpRx.gov on the business remains uncertain and could be material.

Management Comments

• "As these dynamics evolve, how affordability is presented and experienced by consumers is becoming increasingly important, shaping not just awareness, but whether patients ultimately move forward with treatments."
• "For us, this evolution is both an opportunity and a clear validation of our mission."
• "While our prescription transactions offering remains foundational, given the evolving dynamics of prescription access and pharmacy economics, including the growing relevance of self-pay and direct-to-consumer distribution models, we are continuing to position our Pharma Direct offering as a key driver of growth."
• "Accordingly, while this transition may impact near-term financial performance, we believe it enhances our long-term growth prospects and ability to create sustainable value."
• "As our business continues to evolve, we are reassessing the Monthly Active Consumers metric as a primary indicator of performance to ensure it aligns with how we measure growth and profitability."

Industry Context

StockSavvy.ai notes that GoodRx's Q1 2026 results reflect significant shifts in the U.S. healthcare and pharmacy landscape. The company's strategic pivot towards Pharma Direct and subscription services aligns with broader industry trends of increasing demand for transparency, direct-to-consumer engagement, and employer-sponsored affordability solutions, driven by rising out-of-pocket costs and evolving government initiatives like TrumpRx.gov. However, the decline in prescription transaction revenue highlights the challenges posed by retail pharmacy consolidation and PBM network changes.

Comparison to Industry Standards

• GoodRx's revenue decline of 4% in Q1 2026 contrasts with the general growth observed in the digital health and pharmacy services sector, which has seen increased adoption of telehealth and prescription management platforms.
• The significant increase in Pharma Direct revenue (82%) suggests GoodRx is successfully capturing market share in a growing segment focused on manufacturer-supported patient access programs, a trend seen across the pharmaceutical industry.
• The decline in Monthly Active Consumers (MACs) to 5.3 million from 6.4 million year-over-year indicates a potential underperformance relative to competitors who may be less exposed to the direct impacts of retail pharmacy network disruptions.
• The company's Adjusted EBITDA margin of 30.0% remains robust, though lower than the previous year's 34.4%, indicating continued operational efficiency but also pressure on profitability from increased cost of revenue and strategic investments.

Legal Proceedings

• Consumer privacy class action: A settlement agreement for $25.0 million, plus $5.5 million for indemnification, is recorded as a probable loss, subject to court approval. The court has denied preliminary approval multiple times, requesting additional information.
• Consumer state litigations: Lawsuits filed in Arkansas and Minnesota regarding alleged violations of discount card distribution statutes. The Arkansas case resulted in a Consent Judgment with immaterial monetary relief. The Minnesota case saw claims dismissed as time-barred, but the plaintiff has filed an appeal.
• Other pending proceedings, claims, and litigation that may require expenditure of significant funds and diversion of resources.

Related Party Transactions

• In March 2025, GoodRx repurchased 20.0 million shares of Class A common stock from related parties (Francisco Partners and Idea Men, LLC, and Spectrum Equity) for $84.9 million, at a discount to the market price.

Stakeholder Impact

• Shareholders: Negative impact due to decreased revenue, net income, and Adjusted EBITDA, and a decline in Monthly Active Consumers. Potential long-term upside from strategic shift to Pharma Direct and subscriptions.
• Employees: Potential impact from restructuring and cost-saving initiatives, though specific details are not provided.
• Customers (Consumers): Continued access to prescription savings through various offerings, with potential for expanded access via Pharma Direct and new initiatives like TrumpRx.gov.
• Pharmacies: Continued partnerships, but potential shifts in business models due to retail pharmacy consolidation and PBM renegotiations.
• Pharmaceutical Manufacturers: Increased engagement opportunities through Pharma Direct and the TrumpRx.gov platform.
• Creditors: Company remains in compliance with debt covenants, and liquidity appears adequate for the next twelve months.

Next Steps

• Continue to position Pharma Direct offering as a key driver of growth.
• Increase investment in Pharma Direct and subscription offerings.
• Develop new ways for manufacturers to engage patients on GoodRx.
• Monitor the impact of TrumpRx.gov on business, offerings, and results of operations.
• Vigorously defend against claims in the Mullens Foundation and Minnesota Teamsters Service Bureau matters.
• Continue to evaluate the Monthly Active Consumers metric as a primary indicator of performance.

Key Dates

Recommendation

While the company faces significant headwinds with declining prescription transaction revenue and net income, its strategic shift towards Pharma Direct and subscription services shows promise for long-term growth. The robust liquidity and ongoing efforts to adapt to industry changes warrant a 'hold' rating, allowing investors to monitor the execution of its strategy and the impact of evolving market dynamics.

Keywords

GoodRx, Form 10-Q, Quarterly Report, Prescription Transactions, Pharma Direct, Subscription Revenue, Healthcare Platform, PBM, Retail Pharmacy, Financial Results, Revenue, Net Income, Adjusted EBITDA, Consumer Privacy, Legal Proceedings, TrumpRx.gov